Latest news with #Cannabix
Yahoo
5 days ago
- Business
- Yahoo
Omega Laboratories Delivers Marijuana Breath Test Validation Packet to Cannabix Technologies Inc. - Completing Major Milestone under Strategic Partnership
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the 'Company or Cannabix') reports that Omega Laboratories Inc. of Ohio, USA ('Omega Laboratories' or 'Omega') a leading drug testing laboratory renowned for its comprehensive services has delivered a Validation Packet for Omega's Laboratory Developed Test Method to test delta9 THC analytes in relation to the Cannabix Marijuana Breath Test ('MBT') technology (Figure 1). The Validation Packet was performed in Omega's ISO/IEC 17025 accredited laboratory environment following their Quality Management System. This validation included a test method for the simultaneous quantification of Δ-9-tetrahydrocannabinol (THC), Δ-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath aerosols collected using Cannabix Technologies' Breath Collection Unit (BCU) and Breath Cartridges (BC). The delivery of the Validation Packet completes a major milestone under the strategic partnership and development agreement ('SPDA') between Cannabix and Omega. This establishes Omega and Cannabix as the premier technology for collecting and testing breath for recent marijuana usage. Cannabix's MBT is a lab-based, collect and send solution, focused on 'recent use' detection of delta-9 THC as opposed to urine, blood and saliva methods (that can detect delta-9 THC many hours, days, or even weeks after consumption). (1) Omega Laboratories is an international industry leader in forensic drugs of abuse testing for over twenty years. Omega has multiple federal as well as international certifications and accreditations for its world class facility and has extensive experience in novel technology for detection of drugs of abuse. Cannabix and Omega are moving quickly to launch with select key clients and ramping up commercialization efforts for the Marijuana Breath Test. Omega Laboratories is currently integrating breath testing using Cannabix Breath Cartridges into its suite of services and testing protocols. Among various initiatives underway the Company and Omega are working together on marketing, distribution, support, manufacturing and logistics for the 1. Cannabix Marijuana Breath Test (BCU and Breath Cartridge) Under the SPDA, in consideration for the completion and delivery of the Validation Packet by Omega, the Company will convert 3 million Special Warrants into Special Warrant Shares to Omega. Furthermore, Omega will have the right to appoint one person to the board of directors of the Company in due course. (1) Olla P, Ishraque MT, Bartol S. 2020. Evaluation of Breath and Plasma Tetrahydrocannabinol Concentration Trends Postcannabis Exposure in Medical Cannabis Patients. Cannabis and Cannabinoid Res.; 99-104. About Omega Laboratories, Inc. Omega Laboratories, headquartered in Mogadore, Ohio with an additional state-of-the-art facility in Ontario, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 24 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine and Breath specimens. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless Custody & Control Form system (oCCF) in fourteen languages, licensure of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers new laboratories in countries that have demand for local service providers. About Cannabix Technologies Inc. Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring We seek Safe Harbor. On behalf of the Board of Directors 'Rav Mlait' CEOCannabix Technologies Inc. For further information, contact the Company at The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking StatementsThis news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the strategic partnership and development agreement with Omega Laboratories; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that Omega may not complete all or any of the milestones as contemplated strategic partnership and development agreement with Omega Laboratories; that the CSE may not approve the issuance of the securities; that the Company's development of breathalyzer technology will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any 'patent pending' or 'provisional patents' technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements. A photo accompanying this announcement is available at in to access your portfolio
The Market Online
30-05-2025
- Business
- The Market Online
Diversify away from cannabis retail with this technology stock
While overproduction, inflation and the glacial pace of legalization have humbled the top Canadian cannabis stocks, such as Tilray (TSX:TLRY) and Canopy Growth (TSX:WEED), from large-cap glory to small-cap question marks, there are certain companies that have managed to generate long-term shareholder value, despite the volatility of a nascent industry, giving investors every reason to expect continued growth into the future. A stock well worth your attention under this lens is Cannabix Technologies (CSE:BLO), market capitalization C$69.09 million, a technology developer specializing in cannabis and alcohol breathalyzers for workplaces, law enforcement, laboratories and other critical settings. The company has been on a role over the past 12 months, achieving positive third-party testing for its alcohol and cannabis-detection technologies, reducing net losses by over 75 per cent from C$2.08 million to C$450,000, in addition to securing a handful of deals that set operations up for revenue generation. These include: Cannabix's latest milestone, a contract manufacturing deal with Price Industries in Winnipeg, Manitoba, announced earlier this week, continues to demonstrate the company's ability to attract well-established partners and pave out its long-term growth runway. The company's diligent product development and consistency at closing deals have earned investors a 76.47-per-cent return year-to-date, an over 250-per-cent return from the five-year low in 2023, and an over 350 per cent return since adopting the Cannabix name in 2014, all of which has come before reporting any revenue on the balance sheet. Once initial orders roll in and Cannabix's top line starts to put up positive numbers, look for the broader market to pile in and reward the patience of long-term investors. While there's no specific timeline for this, the company is well-capitalized to continue building strategic relationships and go-to-market momentum with over C$2.8 million in cash as of January 2025. Join the discussion: Find out what everybody's saying about this alcohol and cannabis breathalyzer technology stock on the Cannabix Technologies Inc. Bullboard and check out the rest of Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
Ottawa Citizen
14-05-2025
- Business
- Ottawa Citizen
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer
Article content Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings Article content Article content VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the 'Company or Cannabix') developer of marijuana and alcohol breath devices is pleased to report that it has entered into an exclusive distribution agreement ('Agreement') with Breathalyser Sales & Service Pty Ltd., ('Breathalyser SSP') for Australia, New Zealand and the Pacific Islands for its BreathLogix autonomous (unmanned) alcohol breathalyzer devices (Figures 1 and 2). This marks Cannabix's first international distribution and sales agreement for its BreathLogix alcohol screening product line. BreathLogix rapidly checks breath alcohol, simultaneously takes a photo of the user, alerts managers in real-time to help avoid injury and damage due to alcohol impairment. Article content Article content Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use, offering well established alcohol product lines like Draeger and AlcoMeasure for the Australian market with regional offices in Perth, Melbourne and Brisbane. Breathalyser SSP has clients in a range of sectors including mining, oil and gas, industrial, trucking, warehousing and technology. Article content Highlights Article content Cannabix enters first international distribution and sales agreement for the BreathLogix autonomous (unmanned) alcohol breathalyzer product line. BreathLogix will be targeted to mining, oil and gas, industrial, trucking, warehousing industries. The exclusive distribution agreement is for an initial 2-year term and covers the territories of Australia, New Zealand and the Pacific Islands. The Australian market for employer pre-access wall mounted alcohol screening devices is mature and well developed. The Company is quickly advancing both its Marijuana Breath Test (MBT) with key validation work established in March, and its BreathLogix alcohol technology with first distribution agreements announced for Canada, Australia, New Zealand and the Pacific Islands. The Company is pursuing distribution partners in the United States. Article content Rav Mlait, CEO of Cannabix Technologies stated, 'Cannabix is actively transitioning from research and development to delivering innovative new technologies in breath testing to the market. We are very pleased be partnering with Breathalyser Sales & Service Pty Ltd of Australia, who have many years of experience with various industries deploying pre-access alcohol testing to improve employee safety.' Article content Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, 'BreathLogix delivers several key features that are important to employers including the ability to rapidly test for breath alcohol, integration capabilities, replaceable sensor cartridge technology and cloud reporting to name a few. We are Australia's oldest distributor and leader in supplying drug and alcohol testing equipment. Pre-access, autonomous employee alcohol screening is a major segment of our business, and we look forward to representing the BreathLogix product line.'
Business Upturn
14-05-2025
- Business
- Business Upturn
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the 'Company or Cannabix') developer of marijuana and alcohol breath devices is pleased to report that it has entered into an exclusive distribution agreement ('Agreement') with Breathalyser Sales & Service Pty Ltd., ('Breathalyser SSP') for Australia, New Zealand and the Pacific Islands for its BreathLogix autonomous (unmanned) alcohol breathalyzer devices (Figures 1 and 2). This marks Cannabix's first international distribution and sales agreement for its BreathLogix alcohol screening product line. BreathLogix rapidly checks breath alcohol, simultaneously takes a photo of the user, alerts managers in real-time to help avoid injury and damage due to alcohol impairment. Breathalyser SSP is a leading distributor of alcohol and drug testing devices for employers and personal use, offering well established alcohol product lines like Draeger and AlcoMeasure for the Australian market with regional offices in Perth, Melbourne and Brisbane. Breathalyser SSP has clients in a range of sectors including mining, oil and gas, industrial, trucking, warehousing and technology. Highlights Cannabix enters first international distribution and sales agreement for the BreathLogix autonomous (unmanned) alcohol breathalyzer product line. BreathLogix will be targeted to mining, oil and gas, industrial, trucking, warehousing industries. The exclusive distribution agreement is for an initial 2-year term and covers the territories of Australia, New Zealand and the Pacific Islands. The Australian market for employer pre-access wall mounted alcohol screening devices is mature and well developed. The Company is quickly advancing both its Marijuana Breath Test (MBT) with key validation work established in March, and its BreathLogix alcohol technology with first distribution agreements announced for Canada, Australia, New Zealand and the Pacific Islands. The Company is pursuing distribution partners in the United States. Rav Mlait, CEO of Cannabix Technologies stated, 'Cannabix is actively transitioning from research and development to delivering innovative new technologies in breath testing to the market. We are very pleased be partnering with Breathalyser Sales & Service Pty Ltd of Australia, who have many years of experience with various industries deploying pre-access alcohol testing to improve employee safety.' Ben Smit, Managing Director of Breathalyser Sales & Service Pty Ltd., stated, 'BreathLogix delivers several key features that are important to employers including the ability to rapidly test for breath alcohol, integration capabilities, replaceable sensor cartridge technology and cloud reporting to name a few. We are Australia's oldest distributor and leader in supplying drug and alcohol testing equipment. Pre-access, autonomous employee alcohol screening is a major segment of our business, and we look forward to representing the BreathLogix product line.' Figure 1. BreathLogix Alcohol Screening Devices Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening BreathLogix Alcohol Screening Devices BreathLogix rapidly checks for breath alcohol and simultaneously takes a photo of the user to confirm and record identity. The device delivers precise Blood Alcohol Content (BAC) levels on the screen and sends real-time test reports via SMS and e-mail, alerting managers to positive BAC results so they can take immediate action to avoid damage and injury. All test results are logged and managed on a dedicated 'Connect' web portal. BreathLogix can be integrated with doors, turnstiles, gates, facial recognition, fingerprint readers and motor vehicle key fleet management systems for pre-access alcohol testing. Furthermore, the device can be used for start-of-shift testing, mandated testing, pre-employment testing, return-to-work testing, random and post-incident testing. BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance. About Cannabix Technologies Inc. Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. We seek Safe Harbor. On behalf of the Board of Directors 'Rav Mlait' CEO Cannabix Technologies Inc. For further information, contact the Company at [email protected] The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Statements This news release contains certain 'forward-looking statements' within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as 'anticipates,' 'plan,' 'continue,' 'expect,' 'project,' 'intend,' 'believe,' 'anticipate,' 'estimate,' 'may,' 'will,' 'potential,' 'proposed,' 'positioned' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies ; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company's development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any 'patent pending' or 'provisional patents' technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements. Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
The Market Online
28-04-2025
- Business
- The Market Online
Cannabix signs distribution deal with Alco Prevention Canada
Cannabix Technologies (CSE:BLO), an innovator in cannabis and alcohol breathalyzers, signed a non-exclusive North American distribution agreement with Alco Prevention Canada Montreal-based Alco Prevention boasts 4,000 points of sale and representation by 45 agents worldwide Cannabix develops cannabis and alcohol breathalyzer technologies for workplaces, law enforcement and other retail and professional environments Cannabix stock has added 96.88 per cent year-over-year but only 50 per cent since 2020 Cannabix Technologies (CSE:BLO), an innovator in cannabis and alcohol breathalyzers, signed a non-exclusive North American distribution agreement with Alco Prevention Canada. Montreal-based Alco Prevention specializes in consumer electronic breathalyzers, breathalyzer rentals and drug screening tests with 4,000 points of sale and representation by 45 agents worldwide. The agreement covers Cannabix's Breath Logix autonomous alcohol breathalyzer devices, whose patent pending pre-calibrated cartridge system promises to save time and money associated with calibration equipment and site visits from technicians. The technology can also take pictures to record identity and send blood alcohol content readings via text message, e-mail and dedicated web portal while logging them for future reference. Cannabix is in numerous discussions with other distributors in North America and internationally. Leadership insights 'The Breath Logix alcohol device is one of the most compact and feature-rich devices I have seen in a long time,' Stephane Maurais, general manager of Alco Prevention, said in a statement. 'The device is well-suited for employer pre-access, work sites, construction, bars, hotels, restaurants and other safety sensitive environments. The device allows employees and patrons to self-test for breath alcohol, avoiding the cost of having to pay an administrator – this saves time and money for customers and makes workplace safety programs easier to deploy. We are very pleased to represent this Canadian-built product.' 'Cannabix is delivering truly innovative new technologies in breath testing to the marketplace,' added Rav Mlait, Cannabix Technologies' chief executive officer. 'Breath testing for marijuana and alcohol is a growing segment, ripe for innovation and disruptive technologies – this has been our focus and we look forward to reaching new milestones in 2025.' About Cannabix Technologies Cannabix develops cannabis and alcohol breathalyzer technologies for workplaces, law enforcement and other retail and professional environments. Cannabix stock (CSE:BLO) is up by 10.53 per cent on the news trading at C$0.63 as of 10:58 am ET. The stock has added 96.88 per cent year-over-year but only 50 per cent since 2020. Join the discussion: Find out what everybody's saying about this cannabis technology stock's deal with Alco Prevention Canada on the Cannabix Technologies Inc. Bullboard and check out Stockhouse's stock forums and message boards. The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here. (Top image of Cannabix's Breath Logix alcohol screening devices: Cannabix Technologies)
